NCT00682448 is a Phase 4 clinical trial of Metformin in Metabolic Complications, sponsored by Rush University Medical Center.

Who is sponsoring NCT00682448?

NCT00682448 is sponsored by Rush University Medical Center.

What drugs are being tested in NCT00682448?

Interventions in NCT00682448: Metformin, Placebo.

What condition does NCT00682448 study?

NCT00682448 studies Metabolic Complications.

Is NCT00682448 still recruiting?

NCT00682448 is currently completed. Last updated 12 January 2021.

Are results published for NCT00682448?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-01-12 · How we verify

NCT00682448

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metformin to Prevent the Metabolic Complications of Olanzapine

Completed Phase 4 Results posted Last updated 12 January 2021

What this trial tests

Phase 4 trial testing Metformin in Metabolic Complications in 25 participants. Completed in 1 August 2011.

Timeline

1 August 2007

Primary endpoint
1 August 2011

1 August 2011

Quick facts

Lead sponsor	Rush University Medical Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	25
Start date	1 August 2007
Primary completion	1 August 2011
Estimated completion	1 August 2011
Sites	1 location across United States

Drugs / interventions tested

Metformin (metformin) — full drug profile →
Placebo

Conditions studied

Metabolic Complications — all drugs for Metabolic Complications →

Sponsor

Rush University Medical Center

Who can join

18 and older, any sex, with Metabolic Complications. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Weight Gain
Time frame: Baseline and 6 months
Change from Baseline in weight

Sponsor's own description

We hypothesize that metformin co-administered with olanzapine will be well tolerated and associated with significantly less insulin resistance, weight gain and dyslipidemia as compared to olanzapine plus placebo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07007221 — Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV · Phase 2 · not yet recruiting
NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting

Other Rush University Medical Center trials

Trials by the same sponsor.

NCT07278076 — Clinical Decision-Making During FEES: The Impact of Residue Amount and Location · NA · not yet recruiting
NCT07088120 — PRECISION-CPR: PRecision-Controlled Ventilation in CPR · NA · not yet recruiting
NCT06894719 — Oral Tranexamic Acid After Total Knee Arthroplasty · Phase 4 · not yet recruiting
NCT06229392 — A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer · Phase 1 · withdrawn
NCT07452406 — Protocolized Weaning of High-Flow Nasal Cannula in Adult Patients · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00682448 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rush University Medical Center
Last refreshed: 12 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00682448.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing